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Objectives. We examined the effects of oral administration of
vitamin E, an antioxidant, on endothelium-dependent vasodila-
tion in patients with coronary spastic angina.
Background. We have recently reported that endothelium-
dependent vasodilation is impaired in patients with coronary
spastic angina (CSA). Furthermore, it is known that oxidative
stress may play an important role in the impairment of
endothelium-dependent vasodilation in cardiovascular diseases.
Methods. With the ultrasound technique, flow-dependent vasodi-
lation of the brachial arteries during reactive hyperemia was exam-
ined before and after treatment for a month with either oral
administration of vitamin E (a-tocopherol acetate, 300 mg/day) or
placebo, which is randomly assigned, in patients with CSA (n 5 60).
Results. Before treatment, patients with CSA had impaired
flow-dependent vasodilation, lower plasma levels of a-tocopherol
and higher plasma levels of thiobarbituric acid reactive sub-
stances (TBARS), as compared with age- and sex-matched control
subjects (n 5 60) (flow-dependent vasodilation: 3.1 6 1.8 vs. 7.1 6
2.5%, p < 0.001; a-tocopherol levels: 8.9 6 1.8 vs. 10.8 6 1.8
mg/ml, p < 0.001). In patients with CSA, treatment with vitamin
E restored flow-dependent vasodilation (3.1 6 1.7 vs. 8.3 6 2.0%,
p < 0.001), and this improvement was associated with the
decreases in plasma TBARS levels and anginal attacks.
Conclusions. The results indicate that vitamin E treatment
improved endothelium-dependent vasodilation and decreased
plasma TBARS levels in patients with CSA. Thus, increased
oxidative stress may contribute to endothelial dysfunction and
anginal attacks in patients with CSA.
(J Am Coll Cardiol 1998;32:1672–9)
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Coronary spasm plays an important role in the pathogenesis of
not only variant angina but also ischemic heart disease in
general, including other forms of angina pectoris, acute myo-
cardial infarction and sudden death (1–4). We have previously
shown that endothelial nitric oxide (NO) activity is decreased
in patients with coronary spastic angina (CSA) (5), leading to
hyperconstrictive response of coronary arteries to acetylcho-
line and impairment of flow-dependent vasodilation in coro-
nary arteries (6). Furthermore, we showed that flow-mediated
endothelium-dependent vasodilation was impaired in the bra-
chial arteries (7), as well as coronary arteries, in patients with
CSA (6). However, the precise mechanism(s) of the decrease
in endothelial NO and/or the endothelial dysfunction in pa-
tients with CSA remains unknown.
Recently, there is increasing evidence that oxidative stress
plays an important role in the mechanism(s) of endothelial
dysfunction in cardiovascular diseases (8–10). A number of
studies have shown that plasma levels of natural antioxidants
are lower in cardiovascular diseases (11,12). Furthermore,
supplementation of antioxidant vitamins has been shown to
restore endothelial function in patients with coronary artery
disease or patients with coronary risk factors (13–15). Thus, it
is possible that increase in oxidative stress may also play a role
in the mechanism(s) of endothelial vasomotor dysfunction in
patients with CSA.
We examined the effects of vitamin E (a-tocopherol ace-
tate) on endothelium-dependent vasodilation of the brachial
arteries in patients with coronary spastic angina.
Methods
Study subjects. The study included 60 consecutive patients
with CSA (mean age, 60.3 6 7.3 years, ranging from 41 to 70
years, 31 men) in whom spontaneous angina occurred at rest.
All of the patients with CSA had angiographically normal
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coronary arteries and showed angiographically documented
coronary spasm associated with ischemic ST segment changes
after intracoronary injection of acetylcholine, as reported
previously (16). The study also included 60 control subjects
(mean age, 61.2 6 6.6 years, ranging from 42 to 71 years, 28
men). These control subjects were selected to match the risk
factors for atherosclerosis to those in patients with CSA, as
shown in Table 1. The control subjects underwent diagnostic
cardiac catheterization for evaluation of chest pain. They had
angiographically normal coronary arteries and did not show
coronary spasm after intracoronary injection of acetylcholine.
Control subjects were studied to compare the baseline data
with those in patients with CSA.
None of the study patients had previous myocardial infarc-
tion, congestive heart failure or other serious diseases. Written
informed consent was obtained from all patients before the
study. The study was in agreement with the guidelines ap-
proved by the ethics committee at our institution.
Study protocol. Patients with CSA were randomly assigned
to the two treatment groups, either vitamin E group (a-
tocopherol acetate, 300 mg/day) or placebo group, by means of
a computerized randomization, as shown Figure 1. All patients
with CSA were treated with diltiazem (200 mg/day), a calcium
antagonist. No other medications affecting the arterial vaso-
motor tone and plasma lipid peroxidation were administered
to any of the study patients. Measurements of flow-dependent
vasodilation and blood sampling for assays of thiobarbituric
acid reactive substances (TBARS) and a-tocopherol were
performed before and 4 weeks after treatment with either
placebo plus diltiazem or vitamin E plus diltiazem in both
treatment groups. Furthermore, the number of anginal attacks
was also recorded before and 4 weeks after treatment in both
groups.
Measurement of flow-dependent vasodilation in the bra-
chial arteries was performed in a quiet and temperature-
controlled (22°C to 24°C) room in the fasting state in the early
morning. Measurements were taken in the exact same manner
between the before and after the treatment. All medications
except sublingal nitroglycerin were withdrawn for at least 24
hours before the measurements were taken. No study patients
had taken nitroglycerin within 6 hours of the study. All subjects
abstained from smoking for at least 8 hours before the studies.
Heart rate and blood pressure were monitored continuously
during the study period.
Ultrasound studies. Vasodilator responses in the brachial
arteries were measured by the ultrasound technique validated
previously by our study and by others (7,17–20). Diameter of
the brachial artery was measured from B-mode ultrasound
images, using a 7.5-MHz linear array transducer (SSH-160A
ultrasound system, Toshiba Corp., Japan). Flow velocity of the
brachial artery was measured using a pulsed Doppler signal at
a 70° angle to the vessel, with the range gate (1.5 mm) in the
center of the artery. The brachial artery was scanned in the
antecubital fossa in a longitudinal fashion. Gain setting was
optimized at the beginning of the study and was kept constant
throughout the recording period. When a satisfactory trans-
ducer position was found, the surface of the skin was marked,
and the arm remained in the same position throughout the
study.
The subjects lay quietly for 10 min before the scan. After
baseline measurements of the diameter and flow velocity in the
brachial artery, a blood pressure cuff placed around the
forearm was inflated with a pressure of 250 to 300 mm Hg for
5 min, and then the cuff was released. Diameter and flow
velocity were continuously measured during cuff inflation and
Abbreviations and Acronyms
ANOVA 5 analysis of variance
CSA 5 coronary spastic angina
NO 5 nitric oxide
TBARS 5 thiobarbituric acid reactive substances
Figure 1. Diagram of the study.
Table 1. Clinical Characteristics of Study Subjects
Coronary Spastic Angina (n 5 60)





Age (yr) 60.7 6 7.3 59.9 6 7.4 61.2 6 6.6
Men/Women 16/14 15/15 28/32
No. of smokers (%) 16 (53.3) 14 (46.7) 29 (48.3)
Total cholesterol (mg/dl) 178.0 6 42.8 174.4 6 40.7 178.5 6 49.8
HDL cholesterol (mg/dl) 46.6 6 10.6 47.0 6 10.1 48.3 6 12.1
Fasting blood sugar (mg/dl) 86.3 6 9.4 83.9 6 11.5 83.1 6 11.2
Body-mass index (kg/m2) 22.8 6 4.0 23.0 6 3.7 23.3 6 3.8
Values are expressed as mean value 6 SD. HDL: high density lipoprotein.
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after cuff deflation. Flow-mediated dilator response was used
as a measure of endothelium-dependent vasodilation. There-
after, the subjects lay quietly for 15 min, by which time the
diameter and flow velocity had returned to baseline levels.
Then, sublingal nitroglycerin (300 mg) was administered, and
3 min later the last measurements were performed. Response
to nitroglycerin was used as a measure of endothelium-
independent vasodilation.
Images were recorded on a super-VHS videocassette re-
corder (model BR-S601M, Victor Corp., Japan), and brachial
arterial diameters were measured from the tape with ultrasonic
calipers by two observers who were blinded as to the protocols
of the study and the subject grouping. Measurements were
taken from the anterior to the posterior “m” line (the interface
between media and adventitia) at end diastole, incident with
the R wave on a continuously recorded electrocardiogram
(7,17–21). Diameter at four cardiac cycles was analyzed for
each scan, and the measurements were averaged. Diameter
measurements for the reactive hyperemia were taken 45 to 90 s
after cuff deflation. Responses of the vessel diameters to the
reactive hyperemia and nitroglycerin were expressed as a
percent increase of the baseline value of the diameter. Blood
flow was calculated by multiplying the velocity-time integral of
the Doppler flow signal by heart rate and the vessel cross-
sectional area. Increase in brachial blood flow was calculated
as a maximum flow recorded in the first 15 s after cuff deflation
and was expressed as a percent increase of the baseline value
of the flow.
In our studies, the interobserver variability for repeated
measurement of resting arterial diameter was 0.06 6 0.03 mm.
The intraobserver variability for repeated measurement of
resting arterial diameter was 0.01 6 0.09 mm. Furthermore,
when these studies were performed at the same time on two
separate days in 20 controls, the between-occasions, within-
patients difference for measurement of the percent increase in
arterial diameter during reactive hyperemia was 1.4 6 1.2%.
Coronary angiography. Quantitative coronary angiography
was performed to examine correlation of endothelium-
dependent vasodilation between brachial arteries and coronary
arteries, according to a validated technique (5,6). The method
of injecting acetylcholine for provocation of coronary spasm
has been detailed previously (5,16). Endothelium-dependent
vasodilator responses of epicardial coronary arteries to acetyl-
choline at a dose of 50 mg/min was evaluated to compare with
the endothelium-dependent vasodilation of brachial arteries.
Biochemical assays. Blood sampling was performed just
before the ultrasound studies. The plasma levels of
a-tocopherol were determined by high performance liquid
chromatography (22). Levels of lipid peroxides in plasma were
determined by measuring the TBARS (20,23). Briefly, 2.0 ml
of trichloroacetic acid-thiobarbituric acid (TBA)-HCl reagent
was added to 1.0 ml of sample and vortexed. To minimize
peroxidation during the assay procedure, butylated hydroxy-
toluene was added to the TBA reagent mixture. The results
were expressed as malondialdehyde equivalent content (nmol
MDA/ml plasma).
Statistical analysis. The changes in hemodynamic param-
eters, percent increase in brachial arterial diameter, plasma
a-tocopherol levels, plasma TBARS levels and number of
anginal attacks were assessed by two-way analysis of variance
(ANOVA) with repeated measures followed by post hoc
testing with Sheffe’s test by computer statistical software
package SAS, version 6.12. Comparisons of data between
patients with CSA and control subjects were performed by
two-tailed unpaired t test for continuous variables, or chi-
square test for categorical variables. Comparisons of data
before treatment between placebo group and vitamin E group
in patients with CSA were performed by two-tailed unpaired t
test for continuous variables, or chi-square test for categorical
variables.
Correlation between the percent increases in brachial arte-
rial diameter during reactive hyperemia before treatment
versus the changes of coronary arterial diameter in response to
acetylcholine at a dose of 50 mg/min was made using linear
regression analysis.
Statistical significance was defined as p , 0.05. Data are
expressed as mean 6 SD.
Results
Data Before Treatment in All Study Subjects
Clinical characteristics. There were no significant differ-
ences in the clinical characteristics between patients with CSA
and controls (Table 1) and between placebo group and vitamin
E group in patients with CSA (Table 1).
Hemodynamic variables. There were no significant differ-
ences in the baseline values of heart rate, blood pressure,
resting arterial diameter, resting arterial blood flow and per-
cent increase in arterial blood flow during reactive hyperemia
between patients with CSA and controls (Table 2) and between
placebo group and vitamin E group in patients with CSA
(Table 2).
Flow-dependent vasodilation of the brachial artery. Flow-
dependent vasodilation was significantly decreased in patients
with CSA as compared with controls (3.1 6 1.8 vs. 7.1 6 2.5%,
p , 0.001) (Fig. 2, A). There was no significant difference in
percent increase in arterial diameter after nitroglycerin admin-
istration between patients with CSA and controls (Table 2).
Flow-dependent vasodilation and percent increase in arterial
diameter after nitroglycerin administration were not signifi-
cantly different between placebo group and vitamin E group in
patients with CSA before treatment (Fig. 3, Table 2).
Plasma levels of vitamin E and TBARS. Plasma levels of
a-tocopherol were lower in patients with CSA than in controls
(8.9 6 1.7 vs. 10.8 6 1.8 mg/ml, p , 0.001) (Fig. 2, B). Plasma
levels of TBARS were higher in patients with CSA than in
controls (6.6 6 1.3 vs. 4.7 6 1.0 nmol/ml, p , 0.001) (Fig. 2, C).
The levels of a-tocopherol and TBARS were not significantly
different between placebo group and vitamin E group in
patients with CSA before treatment (Fig. 4 and 5).
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Effect of Treatment in Patients With Coronary
Spastic Angina
Hemodynamic variable. There were no significant differ-
ences in the magnitude of changes in hemodynamic variables
(heart rate, mean blood pressure, resting arterial diameter,
resting blood flow and percent increase in arterial blood flow
during reactive hyperemia) between vitamin E group and
placebo group (p 5 NS, ANOVA). Heart rate and mean blood
pressure decreased after treatment in both groups (Table 2),
probably due to the effects of diltiazem.
Flow-dependent vasodilation of the brachial artery. Flow-
dependent vasodilation was greater after treatment as com-
pared with before treatment in both groups (placebo group:
3.0 6 1.9 vs. 5.5 6 2.3%, p , 0.001; vitamin E group: 3.1 6 1.7
vs. 8.3 6 2.0%, p , 0.001) (Fig. 3). Flow-dependent vasodila-
tion after treatment was greater in the vitamin E group than in
the placebo group (p , 0.001) (Fig. 3). The magnitude of
increase in flow-dependent vasodilation was significantly
greater in the vitamin E group than in the placebo group (p ,
0.001, ANOVA) (Fig. 3).
There was no significant difference in the magnitude of
changes of the percent increase in arterial diameter after
nitroglycerin administration between the vitamin E group and
the placebo group (p 5 NS, ANOVA). The percent increase in
arterial diameter after nitroglycerin administration was com-
parable between the before and after treatment in each
treatment group (Table 2).
Plasma levels of vitamin E. Plasma a-tocopherol levels were
increased after treatment as compared with before treatment in
both groups (placebo group: 8.9 6 1.3 to 9.2 6 1.3 mg/ml, p ,
0.02; vitamin E group: 8.9 6 2.1 to 20.3 6 4.7 mg/ml, p , 0.001)
(Fig. 4). Plasma a-tocopherol levels after treatment were signifi-
cantly higher in the vitamin E group than in the placebo group
(p , 0.001) (Fig. 4). The magnitude of increase of plasma
a-tocopherol levels was significantly greater in the vitamin E
group than in the placebo group (p , 0.001, ANOVA) (Fig. 4).
Plasma levels of TBARS. Plasma TBARS levels decreased
after treatment as compared with before treatment in both
groups (placebo group: 6.8 6 0.6 vs. 6.3 6 0.9 nmol/ml, p ,
0.03; vitamin E group: 6.6 6 1.3 vs. 4.7 6 1.0 nmol/ml, p ,
0.001) (Fig. 5). Plasma TBARS levels after treatment were
significantly lower in the vitamin E group than in the placebo
Figure 2. (A) Bar graphs showing
the percent increase in brachial ar-
terial diameter during reactive hy-
peremia before treatment in pa-
tients with coronary spastic angina
(CSA) (solid bar) and controls
(open bar). (B) Bar graphs showing
the plasma a-tocopherol levels be-
fore treatment in patients with CSA
(solid bar) and controls (open bar).
(C) Bar graphs showing the plasma
TBARS levels before treatment in
patients with CSA (solid bar) and
controls (open bar).
Table 2. Hemodynamic Variables of Study Subjects
Coronary Spastic Angina (n 5 60)
Controls
(n 5 60)
Placebo Group (n 5 30) Vitamin E Group (n 5 30)
Before After Before After
Heart rate (beats/min) 63.4 6 5.8 57.0 6 5.9 64.0 6 6.2 57.9 6 5.8 63.1 6 7.0
Mean blood pressure
(mm Hg)
88.0 6 4.6 82.1 6 4.1 87.2 6 4.5 80.9 6 4.2 82.5 6 8.1
Arterial diameter at
rest (mm)
3.86 6 0.20 3.88 6 0.17 3.85 6 0.19 3.87 6 0.18 3.88 6 0.49
Arterial diameter after
cuff deflation (mm)
3.98 6 0.20 4.09 6 0.21 3.97 6 0.22 4.19 6 0.22 4.16 6 0.53
Resting arterial blood
flow (ml/min)
177.9 6 13.2 181.4 6 10.3 175.8 6 11.9 181.0 6 11.3 183.9 6 68.8
Increase in arterial
blood flow (%)




18.3 6 1.5 17.9 6 1.7 18.4 6 1.8 18.0 6 1.7 18.1 6 4.1
Measurements of hemodynamic variables in patients with coronary spastic angina were performed before and after
treatments with either placebo plus diltiazem or vitamin E plus diltiazem. Values are expressed as mean value 6 SD.
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group (p , 0.001) (Fig. 5). The magnitude of decrease of
plasma TBARS levels was significantly greater in the vitamin E
group than in the placebo group (p , 0.001, ANOVA) (Fig. 5).
Number of anginal attacks. The number of anginal attacks
before treatment was comparable between the placebo group
and the vitamin E group (placebo group: 6.8 6 4.3 vs. vitamin
E group: 6.9 6 4.3 times). The number of anginal attacks
decreased after treatment as compared with before treatment
in both groups (placebo group: 6.8 6 4.3 vs. 0.9 6 1.1 times;
vitamin E group: 6.9 6 4.3 vs. 0.2 6 0.5 times). The number of
anginal attacks after treatment was smaller in the vitamin E
group than in the placebo group (0.2 6 0.5 vs. 0.9 6 1.1 times).
However, the difference in the magnitude of decrease of
number of anginal attacks per previous week between the
vitamin E group and the placebo group did not reach a
significant level when tested by ANOVA.
Effect of treatment in nonsmoking patients with coronary
spastic angina. In the subgroup analysis of the nonsmokers
with CSA, flow-dependent vasodilation was greater after treat-
ment as compared with before treatment in both groups
(placebo group: 3.3 6 1.9 vs. 5.4 6 2.4%, p , 0.01; vitamin E
group: 3.3 6 2.0 vs. 8.4 6 2.4%, p , 0.001), and the magnitude
of increase in flow-dependent vasodilation was significantly
greater in the vitamin E group than in the placebo group (p ,
0.01, ANOVA). Plasma TBARS levels were decreased after
treatment as compared with before treatment in both groups
(placebo group: 6.8 6 0.5 vs. 6.4 6 0.2 nmol/ml, p , 0.03;
vitamin E group: 6.7 6 1.5 vs. 4.6 6 1.1 nmol/ml, p , 0.001),
and the magnitude of decrease of plasma TBARS levels was
significantly greater in the vitamin E group than in the placebo
group (p , 0.01, ANOVA).
Relation in the magnitude of endothelium-dependent vaso-
dilation between brachial arteries and coronary arteries. A
significant correlation existed between the flow-dependent
vasodilation of brachial artery versus the changes of coronary
arterial diameter in response to acetylcholine (r 5 0.596, p ,
0.001) (Fig. 6).
Discussion
The present study showed that flow-mediated endothelium-
dependent vasodilation was impaired in patients with coronary
spastic angina, a result that is in agreement with our previous
reports (5–7). The present study further showed that oral
vitamin E administration improved impairment of
endothelium-dependent vasodilation in patients with CSA,
Figure 3. Percent increase in brachial arterial diameter during reactive
hyperemia in patients with coronary spastic angina before and after
treatment in the placebo group and the vitamin E group. *Significant
effect of vitamin E treatment compared with values in placebo group, p ,
.001 by ANOVA. B, diltiazem 1 placebo;©, diltiazem 1 vitamin E.
Figure 4. Plasma a-tocopherol levels in patients with coronary spastic
angina before and after treatment in the placebo group and the
vitamin E group. *Significant effect of vitamin E treatment compared
with values in placebo group, p , .001 by ANOVA. B, diltiazem 1
placebo; ©, diltiazem 1 vitamin E.
Figure 5. Plasma TBARS levels in patients with coronary spastic
angina before and after treatment in the placebo group and the
vitamin E group. *Significant effect of vitamin E treatment compared
with values in the placebo group, p , .001 by ANOVA. B, diltiazem 1
placebo; ©, diltiazem 1 vitamin E.
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whereas it had no effect on the dilator response to nitroglyc-
erin, an endothelium-independent vasodilator. These results
indicate that vitamin E restored the endothelial dysfunction in
patients with CSA. These results are in agreement with
previous in vitro studies of experimental hypercholesterolemia
and atherosclerosis (24,25).
Recently, there is increasing evidence that oxidative stress
may play an important role in the mechanism(s) of endothelial
dysfunction in cardiovascular disease (8–10). In the present
study, plasma levels of a-tocopherol were lower in patients
with CSA than in controls, which is in agreement with the
previous report of Miwa et al. (12). Plasma TBARS levels, an
indicator of lipid peroxidation, were higher in patients with
CSA than in controls. Furthermore, the improvement of
endothelial dysfunction by vitamin E administration was asso-
ciated with a decrease in plasma TBARS levels, suggesting that
vitamin E was effective as an antioxidant and suppressed
oxygen free radicals in patients with CSA.
Possible mechanism of increase in oxidative stress. How-
ever, the precise mechanism of the increased oxidative stress in
patients with CSA still remains undetermined in the present
study. Cigarette smoking is a major risk factor for coronary
spasm (26,27), and it has been shown that cigarette smoke
contains large amounts of free radicals, such as superoxide
anions and hydroxyl radicals (28,29), which could degrade
endothelium-derived nitric oxide (NO) (30,31). Our previous
study showed that increased oxidative stress may contribute to
endothelial dysfunction in the brachial arteries in smokers
(20). Therefore, oxygen free radicals in smoke may have at
least partly contributed to increased oxidative stress in smokers
with coronary spastic angina. However, the beneficial effects of
vitamin E in patients with CSA cannot be completely explained
by the suppression of oxidative stress due to cigarette smoking;
the beneficial effects of vitamin E were also shown in nonsmok-
ers in the present patients with CSA.
Coronary spasm causes repeated myocardial ischemia and
reperfusion, and this may also lead to production of free
radicals (32,33). Previously, we have shown that endothelial
NO bioactivity is decreased in coronary arteries of patients
with coronary spastic angina, and this decrease in endothelial
NO may lead to a hyperconstrictive response of coronary
arteries to acetylcholine stimulation (5) and impairment of
flow-dependent vasodilation of coronary arteries in patients
with CSA (6). We have demonstrated that there are several
mutations or polymorphisms in endothelial NO synthase in
patients with CSA, and their mutations in endothelial NO
synthase are significantly associated with patients with CSA
(34). Thus, there is a possibility that the decrease in endothelial
NO production may primarily occur and may be partly respon-
sible for the increase in oxidative stress in patients with CSA
because NO serves as a superoxide scavenger (8,10,35).
An increase in wall shear stress due to the increase in blood
flow results in the production of NO (36). However, Laurindo
et al. (37) recently reported that the increase in wall shear
stress also triggers the production of free radical species, such
as superoxide anions. Nitric oxide-dependent arterial dilation
during increase in blood flow may be determined by the
balance between endothelial NO and free radicals, both of
which are released by an increase in blood flow. Thus, a
weakening of some element in the antioxidant defense system,
such as plasma vitamin E, intracellular glutathione (38) or
superoxide dismutase, may reduce the activity of endothelium-
derived NO released during the increase in blood flow, leading
to impairment of flow-dependent vasodilation in patients with
CSA.
Effects of diltiazem on endothelial function. It is important
to note that endothelium-dependent vasodilation was also
improved in the placebo group of patients with CSA. This
improvement may be due to the adjunctive administration of
diltiazem. Calcium antagonists, which are very effective in
suppressing coronary spasm (3,4), act by interfering with the
entry of calcium into smooth muscle cells and directly induce
smooth muscle cell relaxation (39). Several reports show that
calcium antagonists restored endothelial dysfunction and po-
tentiated the activity of endothelium-derived NO (40–42).
Furthermore, calcium antagonists are shown to have an anti-
oxidant activity (43). Thus, adjunctive treatment with diltiazem
also may have decreased oxidative stress, and it may have also
improved endothelial dysfunction in the placebo group.
Clinical implications. Vitamin E plus diltiazem adminis-
tration also reduced the number of anginal attacks in associa-
tion with the improvement of endothelium-dependent vasodi-
lation and decrease in plasma TBARS levels in patients with
CSA in the present study. Thus, improvement of redox equi-
librium in patients with CSA may lead to a reduction of
ischemic events in association with the improvement of
endothelium-dependent vasodilation of brachial arteries. A
previous report showed a close relation in the magnitude of
endothelium-dependent vasodilation between coronary arter-
ies and brachial arteries (19), and in the present study, all the
patients with CSA had coronary spasm induced by intracoro-
nary injection of acetylcholine, an endothelium-dependent
Figure 6. Correlation between the percent increases in brachial arte-
rial diameter during reactive hyperemia versus the changes of coronary
arterial diameter in response to acetylcholine at a dose of 50 mg/min in
patients with coronary spastic angina (squares) and controls (circles).
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vasodilator, and there was a significant correlation between the
magnitude of endothelium-dependent vasodilation in brachial
arteries and coronary constrictor response to acetylcholine in
patients with CSA. Thus, it may be possible that redox
equilibrium and endothelial dysfunction are related to the
mechanism(s) of coronary artery spasm.
Study limitations. The effect of vitamin E alone on the
attacks in patients with CSA could not be examined in the
present study for ethical reasons. The treatment with placebo
alone may cause severe myocardial ischemia, leading to fatal
cardiac events such as acute myocardial infarction and ventric-
ular tachycardia in patients with CSA; calcium antagonists
have been shown to be very effective in suppressing coronary
spasm (3,4).
In this study, diltiazem markedly reduced the number of
attacks in both the vitamin E group and placebo group, and
this may have contributed to no statistically significant differ-
ence in the magnitude of decrease in number of attacks
between the two groups by ANOVA. Further studies are
needed to prove whether vitamin E is effective in suppressing
attacks in patients with CSA.
Conclusions. We conclude that endothelium-dependent
vasodilation in the brachial arteries is impaired in patients with
coronary spastic angina, and that this impairment is improved
by vitamin E administration in association with the decreases
in plasma TBARS levels and anginal attacks. These findings
suggest that increased oxidative stress may contribute to
endothelial dysfunction and anginal attacks in patients with
CSA.
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